Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Nov 20.

Published in final edited form as: Am Soc Clin Oncol Educ Book. 2018 May 23;38:978–997. doi: 10.1200/EDBK_199765

Table 5.

Effect of ESR1 Mutations on Clinical Outcome in Patients Receiving Endocrine Therapies in SoFEA Trial

Variable	Exemestane		Hazard Ratio (95% CI); p Value
Variable	ESR1 Wild-Type	ESR1-Mutated	Hazard Ratio (95% CI); p Value
Patients (n)	39	18
Median PFS, mo (95% CI)	8.0 (3.0–11.5)	2.6 (2.4–6.2)	2.12 (1.18–3.81); .01
Median OS, mo (95% CI)	22.8 (17.6–32.4)	12.8 (5.7–27.0)	1.65 (0.81–3.38); .16
	ESR1-Mutated
	Fulvestrant Regimens	Exemestane
Patients (n)	45	18
Median PFS, mo (95% CI)	5.7 (3.0–8.5)	2.6 (2.4–6.2)	0.52 (CI, 0.30–0.92); .02
	ESR1 Wild-Type
	Fulvestrant Regimens	Exemestane
Patients (n)	59	39
Median PFS, mo (95% CI)	8.0 (3.0–11.5)	5.4 (3.7–81.)	1.07 (0.68–1.67); .77

Abbreviation: PFS, progression-free survival.